Loading...
Iovance Biotherapeutics, Inc.
IOVA•NASDAQ
Healthcare
Biotechnology
$3.29
$-0.68(-17.13%)
Iovance Biotherapeutics, Inc. (IOVA) Financial Performance & Income Statement Overview
Review Iovance Biotherapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
13698.99%
↑ 13698.99%
Operating Income Growth
14.17%
↑ 14.17%
Net Income Growth
16.18%
↑ 16.18%
Operating Cash Flow Growth
2.44%
↑ 2.44%
Operating Margin
-187.50%
↓ 187.50%
Gross Margin
19.20%
↑ 19.20%
Net Profit Margin
-176.49%
↓ 176.49%
ROE
-49.71%
↓ 49.71%
ROIC
-47.25%
↓ 47.25%
Iovance Biotherapeutics, Inc. (IOVA) Income Statement & Financial Overview
Review Iovance Biotherapeutics, Inc.'s (IOVA) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $73.69M | $58.55M | $31.11M | $715000.00 |
| Cost of Revenue | $45.54M | $39.82M | $36.75M | $12.54M |
| Gross Profit | $28.15M | $18.73M | -$5.64M | -$11.82M |
| Gross Profit Ratio | $0.38 | $0.32 | -$0.18 | -$16.53 |
| R&D Expenses | $72.22M | $68.25M | $62.08M | $79.78M |
| SG&A Expenses | $42.50M | $39.55M | $34.19M | $26.12M |
| Operating Expenses | $114.73M | $107.80M | $96.27M | $105.90M |
| Total Costs & Expenses | $160.27M | $147.62M | $133.02M | $118.44M |
| Interest Income | $9.57M | $4.005M | $3.35M | $3.34M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $11.69M | $0.00 | $10.86M | $9.91M |
| EBITDA | -$74.89M | -$89.07M | -$91.05M | -$107.81M |
| EBITDA Ratio | -$1.02 | -$1.52 | -$2.93 | -$150.79 |
| Operating Income | -$86.58M | -$89.07M | -$101.91M | -$117.72M |
| Operating Income Ratio | -$1.17 | -$1.52 | -$3.28 | -$164.65 |
| Other Income/Expenses (Net) | $9.57M | $4.005M | $3.35M | $3.34M |
| Income Before Tax | -$77.001M | -$85.06M | -$98.56M | -$114.38M |
| Income Before Tax Ratio | -$1.04 | -$1.45 | -$3.17 | -$159.98 |
| Income Tax Expense | $1.56M | -$1.52M | -$1.46M | -$1.41M |
| Net Income | -$78.56M | -$83.54M | -$97.10M | -$112.98M |
| Net Income Ratio | -$1.07 | -$1.43 | -$3.12 | -$158.008 |
| EPS | -$0.26 | -$0.28 | -$0.34 | -$0.42 |
| Diluted EPS | -$0.26 | -$0.28 | -$0.34 | -$0.42 |
| Weighted Avg Shares Outstanding | $304.89M | $303.27M | $284.82M | $266.22M |
| Weighted Avg Shares Outstanding (Diluted) | $304.89M | $303.27M | $284.82M | $266.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan